MedPath

Combangio, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Phase 2
Active, not recruiting
Conditions
Persistent Corneal Epithelial Defect
Interventions
Drug: KPI-012 Vehicle
First Posted Date
2023-02-14
Last Posted Date
2025-09-30
Lead Sponsor
Combangio, Inc
Target Recruit Count
2
Registration Number
NCT05727878
Locations
🇵🇷

Principal Investigator, San Juan, Puerto Rico, Puerto Rico

🇺🇸

Principal investigator, Durham, North Carolina, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.